Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | President & COO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,060 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 2,528 · Balance 196,060 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 21:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 2,528 | $7.14 | $18,059.78 |
DisclosureSEC source: 0001873392-26-000006 · wk-form4_1788470291.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,060 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · derivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,831 Underlying: Common Stock · 15,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F3 · derivative.exercise_date: The shares subject to this option fully vested on November 4, 2023. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 15,000 | $15.33 | $229,953.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:24 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 15,000 | $1.74 | $26,100.00 |
DisclosureSEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 20:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 11,894 | $13.05 | $155,188.15 |
DisclosureSEC source: 0001873392-26-000002 · wk-form4_1773261310.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,588 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,116 | $13.02 | $40,582.78 |
DisclosureSEC source: 0001873392-26-000002 · wk-form4_1773261310.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,482 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 14,038 | $11.76 | $165,036.34 |
DisclosureSEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,598 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 7,223 | $11.66 | $84,205.01 |
DisclosureSEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,636 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 83,200 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · derivative · entry 4 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,200 Underlying: Common Stock · 83,200 shares Expires 2036-03-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 55,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,859 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:03 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,746 | $5.43 | $9,481.13 |
DisclosureSEC source: 0001873392-25-000003 · wk-form4_1757019821.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,059 F1 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 5,144 | $11.68 | $60,074.72 |
DisclosureSEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,805 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 90,800 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · derivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,800 Underlying: Common Stock · 90,800 shares Expires 2035-03-01 F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 60,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,949 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 847 | $16.00 | $13,552.00 |
DisclosureSEC source: 0001689375-24-000056 · wk-form4_1727728325.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,149 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,904 | $15.07 | $28,690.23 |
DisclosureSEC source: 0001689375-24-000054 · wk-form4_1726000407.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,996 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 399 | $15.19 | $6,062.69 |
DisclosureSEC source: 0001689375-24-000054 · wk-form4_1726000407.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,900 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.07 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 171 | $15.13 | $2,586.55 |
DisclosureSEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 5 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,299 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 983 | $15.42 | $15,161.20 |
DisclosureSEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 4 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,470 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 15 | $17.70 | $265.53 |
DisclosureSEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,453 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 156 | $16.93 | $2,640.38 |
DisclosureSEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,468 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 483 | $15.76 | $7,612.61 |
DisclosureSEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,624 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · derivative · entry 4 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,831 Underlying: Common Stock · 20,000 shares Expires 2029-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on November 4, 2020, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 502 | $16.70 | $8,382.40 |
DisclosureSEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,107 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.69 to $16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 26,595 | $16.26 | $432,418.74 |
DisclosureSEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,609 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.67 to $16.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 20,000 | $1.74 | $34,800.00 |
DisclosureSEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,826 | $12.32 | $22,498.69 |
DisclosureSEC source: 0001689375-24-000007 · wk-form4_1709933649.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,204 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.02 to $12.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,486 | $12.28 | $18,246.30 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 5 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,030 F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 409 | $13.37 | $5,467.23 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 4 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,516 F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 343 | $12.42 | $4,261.09 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,925 F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 50,100 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · derivative · entry 6 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,100 Underlying: Common Stock · 50,100 shares Expires 2034-03-01 F7 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,268 F2 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 33,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,268 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 59 | $14.01 | $826.41 |
DisclosureSEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 4 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,168 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 913 | $13.43 | $12,262.69 |
DisclosureSEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,227 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.88 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 436 | $14.46 | $6,305.65 |
DisclosureSEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,140 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · derivative · entry 5 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-09-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,576 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,897 | $18.05 | $70,333.06 |
DisclosureSEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,376 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,200 | $18.00 | $57,605.12 |
DisclosureSEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,273 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2023 Filed Jun 22, 2023 20:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 7,097 | $16.02 | $113,699.62 |
DisclosureSEC source: 0001689375-23-000042 · wf-form4_168746675476462.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,473 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,885 | $14.94 | $132,703.69 |
DisclosureSEC source: 0001689375-23-000042 · wf-form4_168746675476462.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,570 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $15.0090, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,028 | $11.60 | $11,920.89 |
DisclosureSEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,655 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · derivative · entry 3 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:33 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 28,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,683 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:46 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000026 · wf-form4a_168194078070459.xml · derivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:46 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000026 · wf-form4a_168194078070459.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,455 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:54 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,100 | $24.05 | $50,495.13 |
DisclosureSEC source: 0001689375-22-000040 · wf-form4_166742245826942.xml · nonDerivative · entry 1 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 900 | $21.85 | $19,668.96 |
DisclosureSEC source: 0001689375-22-000038 · wf-form4_166691086621050.xml · nonDerivative · entry 3 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.14 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 5,414 | $20.97 | $113,525.62 |
DisclosureSEC source: 0001689375-22-000038 · wf-form4_166691086621050.xml · nonDerivative · entry 2 Dowden Nathan J · CIK 0001873392 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.